EVAX
Price:
$1.49
Market Cap:
$8.06M
Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies for cancers, bacterial diseases, and viral infections. The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Phase IIa trial for adjuvant melanoma; and EVX-03, a DNA-based immunotherapy for the treatment of various cancers. Its programs also include EVX-B1, EVX-B2, and EVX-V1, which are vaccines that are in pre-clinical stage for the treatment of bacterial and viral diseases. The company was incorporated in 2008 and is headquartered in Hørsholm, Denmark.[Read more]
Industry
Biotechnology
IPO Date
2021-02-05
Stock Exchange
NASDAQ
Ticker
EVAX
According to Evaxion Biotech A/S’s latest financial reports and current stock price. The company's current ROE is 5.77%. This represents a change of -875.17% compared to the average of -743.78% of the last 4 quarters.
The mean historical ROE of Evaxion Biotech A/S over the last ten years is 115.71%. The current 5.77% ROE has changed 4.88% with respect to the historical average. Over the past ten years (40 quarters), EVAX's ROE was at its highest in in the December 2023 quarter at 96.43%. The ROE was at its lowest in in the September 2024 quarter at -2623.11%.
Average
115.71%
Median
31.89%
Minimum
-213.38%
Maximum
594.52%
Discovering the peaks and valleys of Evaxion Biotech A/S ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = Infinity%
Maximum Annual ROE = 594.52%
Minimum Annual Increase = -122.80%
Minimum Annual ROE = -213.38%
Year | ROE | Change |
---|---|---|
2023 | 467.86% | 1.37% |
2022 | 31.89% | -34.45% |
2021 | 48.64% | -122.80% |
2020 | -213.38% | 78.45% |
2019 | -119.58% | -120.11% |
2018 | 594.52% | Infinity% |
The current ROE of Evaxion Biotech A/S (EVAX) is less than than its 3-year, greater than its 5-year, and less than than its 10-year historical averages
3-year avg
182.80%
5-year avg
43.09%
10-year avg
115.71%
Evaxion Biotech A/S’s ROE is greater than Sigilon Therapeutics, Inc. (-74.73%), less than Reviva Pharmaceuticals Holdings, Inc. (664.92%), greater than ZyVersa Therapeutics, Inc. (-25512.50%), less than Kiromic BioPharma, Inc. (327.18%), greater than Unicycive Therapeutics, Inc. (-374.14%), greater than Quoin Pharmaceuticals, Ltd. (-126.19%), greater than Allarity Therapeutics, Inc. (-328.22%), greater than Virax Biolabs Group Limited (-115.10%), greater than Biodexa Pharmaceuticals Plc (-101.74%), greater than Lyell Immunopharma, Inc. (-34.64%), greater than Cullinan Oncology, Inc. (-26.54%), greater than Monte Rosa Therapeutics, Inc. (-62.68%), greater than Theseus Pharmaceuticals, Inc. (-12.35%), greater than Revolution Medicines, Inc. (-33.67%), less than eFFECTOR Therapeutics, Inc. (2.18%), greater than Landos Biopharma, Inc. (-73.00%), greater than Apexigen, Inc. (48.27%), greater than Navidea Biopharmaceuticals, Inc. (-173.56%), greater than Angion Biomedica Corp. (-98.89%), greater than Revelation Biosciences, Inc. (-311.33%), greater than Zura Bio Limited (-39.61%), greater than Phio Pharmaceuticals Corp. (-134.57%), greater than TransCode Therapeutics, Inc. (-649.01%),
Company | ROE | Market cap |
---|---|---|
-74.73% | $56.22M | |
664.92% | $38.12M | |
-25512.50% | $2.65M | |
327.18% | $1.69M | |
-374.14% | $55.01M | |
-126.19% | $2.95M | |
-328.22% | $5.63M | |
-115.10% | $8.73M | |
-101.74% | $2.32M | |
-34.64% | $265.26M | |
-26.54% | $730.17M | |
-62.68% | $521.60M | |
-12.35% | $181.50M | |
-33.67% | $9.55B | |
2.18% | $941.00 | |
-73.00% | $71.68M | |
48.27% | $9.57M | |
-173.56% | $100.08K | |
-98.89% | $30.11M | |
-311.33% | $3.24M | |
-39.61% | $178.25M | |
-134.57% | $2.61M | |
-649.01% | $6.64M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Evaxion Biotech A/S using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Evaxion Biotech A/S or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Evaxion Biotech A/S's ROE?
How is the ROE calculated for Evaxion Biotech A/S (EVAX)?
What is the highest ROE for Evaxion Biotech A/S (EVAX)?
What is the 3-year average ROE for Evaxion Biotech A/S (EVAX)?
What is the 5-year average ROE for Evaxion Biotech A/S (EVAX)?
How does the current ROE for Evaxion Biotech A/S (EVAX) compare to its historical average?